Abstract:Repurposing has the objective of targeting existing drugs and failed, abandoned, or yet-to-be-pursued clinical candidates to new disease areas. The open-source model permits for the sharing of data, resources, compounds, clinical molecules, small libraries, and screening platforms to cost-effectively advance old drugs and/or candidates into clinical re-development. Clearly, at the core of drug-repurposing activities is collaboration, in many cases progressing beyond the open sharing of resources, technology, a… Show more
“…Other approaches are set out to use complex mathematical computational models, where drug attributes and possible receptor affinities can be matched with target proteins or receptors known to exist in a particular disease state. 18,19 Such models have made detailed studies of a drugs molecular structure and side chains and then matched them with drugs with similar structural properties that are known to be effective in the target illness. 19 Lastly, there are already in existence vast data banks such as OpenPhacts, DrugBank and the delightfully named 'Promiscuous' that provide a wealth of pharmacological and physicochemical data, as well as information on drugs' protein and active-site structures and associations with related disease states, 20 that lie ready to be mined.…”
Section: Beta Adrenergic Blocking Drugs: First Life Anti-hypertensivementioning
confidence: 99%
“…18,19 Such models have made detailed studies of a drugs molecular structure and side chains and then matched them with drugs with similar structural properties that are known to be effective in the target illness. 19 Lastly, there are already in existence vast data banks such as OpenPhacts, DrugBank and the delightfully named 'Promiscuous' that provide a wealth of pharmacological and physicochemical data, as well as information on drugs' protein and active-site structures and associations with related disease states, 20 that lie ready to be mined. These existence of data banks, together with the fact that a new journal entirely devoted to the subject of drug repositioning is to be launched shortly, 21 suggest that drug repositioning may indeed herald a new dawn in the complex world of drug discovery and development.…”
Section: Beta Adrenergic Blocking Drugs: First Life Anti-hypertensivementioning
“…Other approaches are set out to use complex mathematical computational models, where drug attributes and possible receptor affinities can be matched with target proteins or receptors known to exist in a particular disease state. 18,19 Such models have made detailed studies of a drugs molecular structure and side chains and then matched them with drugs with similar structural properties that are known to be effective in the target illness. 19 Lastly, there are already in existence vast data banks such as OpenPhacts, DrugBank and the delightfully named 'Promiscuous' that provide a wealth of pharmacological and physicochemical data, as well as information on drugs' protein and active-site structures and associations with related disease states, 20 that lie ready to be mined.…”
Section: Beta Adrenergic Blocking Drugs: First Life Anti-hypertensivementioning
confidence: 99%
“…18,19 Such models have made detailed studies of a drugs molecular structure and side chains and then matched them with drugs with similar structural properties that are known to be effective in the target illness. 19 Lastly, there are already in existence vast data banks such as OpenPhacts, DrugBank and the delightfully named 'Promiscuous' that provide a wealth of pharmacological and physicochemical data, as well as information on drugs' protein and active-site structures and associations with related disease states, 20 that lie ready to be mined. These existence of data banks, together with the fact that a new journal entirely devoted to the subject of drug repositioning is to be launched shortly, 21 suggest that drug repositioning may indeed herald a new dawn in the complex world of drug discovery and development.…”
Section: Beta Adrenergic Blocking Drugs: First Life Anti-hypertensivementioning
“…Open-source databases such as DrugBank, the Potential Drug Target Database, Therapeutic Target Database and SuperTarget provide target and drug profiles [2][3][4][5]. These databases feature drug targets, including protein and active site structures, association with related diseases, biological functions and associated signaling pathways [3].…”
Section: Pre-competitive Open-source Drug Discoverymentioning
confidence: 99%
“…ChemProt, a disease chemical biology database, is based on a collection of multiple chemical-protein annotation resources, as well as disease-associated protein--protein interactions [6]. Moving further downstream, compound-specific databases comprise PubChem, ChEMBL and ChemSpider [2]. Hinting at the need for data integration and standardization is Open Babel.…”
Section: Pre-competitive Open-source Drug Discoverymentioning
confidence: 99%
“…Arising then out of these collaborations should be human capacity engagement through educational and other training opportunities. I have discussed the SGC visitor training program as one example and we see the recently established WIPO Re:Search initiative offering educational and training opportunities for researchers within the private sector context [2].…”
Section: The Human Capital Development Challengementioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.